{"entity":{"id":"nct06892548","kind":"trial","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of BNT324 and PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.","summary":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer is a phase 1/2 interventional study registered as NCT06892548 by BioNTech SE, with 594 participants planned, started 2025-05-02 and due to reach its primary completion in 2028-09. Interventions recorded: BNT324 and BNT327.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06892548","url":"https://clinicaltrials.gov/study/NCT06892548"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bnt324","pm8002"],"companies":["biontech","dualitybio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06892548","phase":"1/2","setting":"A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer","sponsor":"BioNTech SE","enrolled":594,"outcomes":[]},"route":"/trials/nct06892548/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bnt324","kind":"drug","name":"BNT324","route":"/drugs/bnt324/"},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"}]}}